


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 - 18. (Cancelled)

19. (Currently Amended) A conjugate having the general formula



wherein

P represents an N-hydroxypropylmethacrylamide-methacrylate copolymer having a molecular weight of 5-6,000 kDa;

~~NAT represents a nuclide activation therapy agent;~~

NCT represents a neutron capture therapy agent;

L represents a linker moiety capable of linking the polymer to the neutron capture therapy agent;

and

n represents an integer from 1 - 1,000;

and wherein the conjugate further comprises a chemotherapeutic agent attached to the polymer via the linker moiety L.

20. (Previously Presented) A conjugate as claimed in claim 19, wherein the polymer is a 2-hydroxypropylmethacrylamide-methacrylate copolymer.

21. (Currently Amended) A conjugate as claimed in claim 19, wherein the polymer has a molecular weight of 5-100~~7~~  
~~preferably 10-70, more preferably 15-45, most preferably 20-40~~  
~~ma~~.

22. (Previously Presented) A conjugate as claimed in claim 19, wherein the ratio of hydroxypropylmethacrylamide to methacrylate is from 20:1 to 1:1.

23. (Canceled)

24. (Currently Amended) A conjugate as claimed in claim ~~23~~ 19, wherein the neutron capture therapy agent contains at least one nuclide selected from  $^6\text{Li}$ ,  $^{10}\text{B}$ ,  $^{22}\text{Na}$ ,  $^{58}\text{Co}$ ,  $^{113}\text{Cd}$ ,  $^{126}\text{I}$ ,  $^{135}\text{Xe}$ ,  $^{148}\text{mPm}$ ,  $^{149}\text{Sm}$ ,  $^{151}\text{Eu}$ ,  $^{155}\text{Gd}$ ,  $^{157}\text{Gd}$ ,  $^{164}\text{Dy}$ ,  $^{184}\text{Os}$ ,  $^{199}\text{Hg}$ ,  $^{230}\text{Pa}$ ,  $^{235}\text{U}$  and  $^{241}\text{Pu}$  in sufficient quantity to undergo a neutron capture reaction.

25. (Previously Presented) A conjugate as claimed in claim 24, wherein the nuclide is  $^{10}\text{OB}$ .

26. (Currently Amended) A conjugate as claimed in claim ~~23~~ 19, wherein ~~NAT~~ NCT represents a boronated amino acid or peptide, a modified carborane cage, a mercaptoborate, a boron-containing porphyrin or phthalocyanine, a boron-containing nucleic acid precursor, or a boron-containing foliate growth factor, hormone, radiation sensitizer, phosphates, phosphonate, phosphoramidates, cyclic thiourea derivative, amine, promazine, hydantoin or barbiturate.

27. (Currently Amended) A conjugate as claimed in claim 19, wherein the ~~NAT~~ NCT agent NCT makes up 1-30%, ~~preferably 5-10%~~, of the overall mass of the conjugate.

28. (Currently Amended) A conjugate as claimed in claim 19, wherein the linker represents a linear or branched  $\text{C}_{1-15}$  alkyl which may be saturated or unsaturated, optionally substituted by

carbonyl, amide, hydroxyl or halogen; a peptide, ~~preferably 1-10 amino acids in length,~~ in which the amino acids may be further substituted with amino, thio, carboxyl, carboxamide or imidazole groups; or a covalent bond.

29. (Currently Amended) A conjugate as claimed in claim 19, wherein n represents an integer ~~form from~~ from 1-500, ~~preferably 1-100, particularly preferably 1-20.~~

30. (Previously Presented)  
Poly(HPMA-co-MA-Gly-Phe-Leu-Gly-B SMel)Gly-Phe-Leu-Gly-Paclitaxel  
[SEQ ID NO: 20].

31. (Previously Presented)  
Poly(HPMA-co-MA-Gly-Phe-Leu-Gly-BSMel)Gly-Phe-Leu-Gly-Doxombicin  
[SEQ ID NO: 20].

32. (Previously Presented) A pharmaceutical composition containing the conjugate as claimed in claim 19.

33. (Previously Presented) A method of treating cancer which comprises administering to a patient in need thereof an effective amount of a medicament comprising the conjugate of claim 19.